moomoo ID:NaN
Log Out
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > ARVN Arvinas > Company Executives
ARVN Arvinas
Post Mkt Price
NamePositionSalaryService DateEducationAgeGenderUpdated
Dr. John G. Houston, PhDDirector, Chief Executive Officer and President12.60M----62male04/27/2022
Mr. Sean A. CassidyChief Financial Officer and Principal Accounting Officer4.24M----52male04/27/2022
Dr. Ian Taylor, PhDChief Scientific Officer4.26M----59male04/27/2022
Mr. Ronald PeckChief Medical Officer4.28M----56male04/27/2022
Dr. Timothy M. Shannon,M.D.Chairman of the Board449.94K----63male04/27/2022
Mr. John Douglas YoungDirector--------male08/19/2022
Dr. Wendy L. Dixon, PhDIndependent Director414.26K----66female04/27/2022
Ms. Leslie V. Norwalk, Esq.Independent Director417.76K----56female04/27/2022
Dr. Briggs W. Morrison, M.D.Independent Director418.26K----63male04/27/2022
Ms. Linda C. BainIndependent Director425.26K----51female04/27/2022
Dr. Laurie Smaldone Alsup, M.D.Independent Director415.26K----68female04/27/2022
Mr. Edward Kennedy, JrIndependent Director414.26K----60male04/27/2022
Mr. Bradley Margus, PhDIndependent Director417.76K----61male04/27/2022
Company Overview More
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.
CEO: Dr. John G. Houston, PhD
Market: NASDAQ
Listing Date: 09/27/2018
Hot List
SymbolLatest price%Chg